Bharat Biotech Announces Phase 3 Results of COVAXIN India’s First COVID-19 Vaccine Demonstrates Interim Clinical Efficacy of 81%

หน้าแรก / News / Bharat Biotech Announces Phase 3 Results of COVAXIN India’s First COVID-19 Vaccine Demonstrates Interim Clinical Efficacy of 81%


https://www.bharatbiotech.com/images/press/covaxin-phase3-efficacy-results.pdf



            
                
                                            Recent NewsBritish Medical Journal Raises Concerns Over Integrity of mRNA Molecules Used in COVID-19 Vaccines After Leaked Documents Raises Questions
Experts happy with India Covaxin efficacy results
Covaxin: Bharat Biotech submits interim phase 3 results to drugs regulator
สธ.แถลงเลื่อนฉีดวัคซีน “เอสตราฯ” รอผลสอบสวน เพื่อความปลอดภัย
Denmark, Norway, Iceland halt use of AstraZeneca vaccine over concerns of blood clots
			
	
		
	



	
		เกี่ยวกับเรา
	
	
		
	



	
		In 1993, Biogenetech started with just 10 staff, distributing diagnostic kits and nuclear medicines.

In the past 25 years, Biogenetech introduced more than 15 innovative vaccines and pharmaceuticals, contributing to the improvements in public health standards in Thailand, protecting our population from numerous infectious diseases!

	



	
	อ่านเพิ่มเติม


        

        
                    
                
                    Related Health Education
                                        
                        
                            
                                
                                    Experts happy with India Covaxin efficacy results                                
                            
                        
                                        
                        
                            
                                
                                    Covaxin: Bharat Biotech submits interim phase 3 results to drugs regulator                                
                            
                        
                                        
                        
                            
                                
                                    สธ.แถลงเลื่อนฉีดวัคซีน “เอสตราฯ” รอผลสอบสวน เพื่อความปลอดภัย                                
                            
                        
                                        
                        
                            
                                
                                    Denmark, Norway, Iceland halt use of AstraZeneca vaccine over concerns of blood clots                                
                            
                        
                                        
                        
                            
                                
                                    เปิด 4 ชื่อบริษัท “วัคซีนโควิด” ขอขึ้นทะเบียนในไทยแล้ว

Related Posts

Bharat Biotech Announces Phase 3 Results of COVAXIN India’s First COVID-19 Vaccine Demonstrates Interim Clinical Efficacy of 81%

Related Health Education